Cancer Science & Therapy

Robert Lechleider

Publications

• Review Article
  Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies
  Author(s): Robert Lechleider and Ira PastanRobert Lechleider and Ira Pastan
  
  Immunotoxins composed of monoclonal antibodies linked to bacterial or plant protein toxins have been studied during the past 30 years as a potential targeted therapy for cancer. A series of refinements in the design of immunotoxins containing the bacterial toxin Pseudomonas exotoxin A (PE) led to the development of the current smaller, more selective, and more stable recombinant immunotoxins that are composed of a truncated form of PE fused to the variable domain of a monoclonal antibody. Immunotoxins targeting CD22, an antigen commonly expressed on B-cell malignancies, including BL22 (also known as CAT-3888) and its improved, higher affinity derivative, moxetumomab pasudotox (also known as HA22 or CAT-8015) are being evaluated in patients with hematologic malignancies. BL22 induced complete remissions in the majority of patients with chemoresistant hairy cell leukemia (HCL) during ph.. Read More»
  DOI: 10.4172/1948-5956.1000057

  Abstract PDF